Elsevier

Clinical Immunology

Volume 233, December 2021, 108879
Clinical Immunology

Review Article
Role of NRF2 and Sirtuin activators in COVID-19

https://doi.org/10.1016/j.clim.2021.108879Get rights and content

Highlights

  • Exploration of novel targets for treatment of COVID-19 is the need of the hour owing to its complpathophysiolo

  • NRF2 is a vital protein which exerts anti-inflammatory role by inhibition of NF-kB, suppression of pro-inflammatory genes.

  • NRF2 is deacetylated by Sirtuins and therefore Sirtuins and NRF2 have a direct association.

  • Absence of SIRT leads to inhibition of NRF2 expression and no anti-oxidative and anti-inflammatory protection for the cell.

  • NRF2 activators and/or SIRT activators can be explored to evaluate their efficacy in treating symptoms of COVID-19.

Abstract

COVID-19 is a pandemic requiring immediate solution for treatment because of its complex pathophysiology. Exploration of novel targets and thus treatment will be life savers which is the need of the hour. 2 host factors- TMPRSS2 and ACE2 are responsible for the way the virus will enter and replicate in the host. Also NRF2 is an important protein responsible for its anti-inflammatory role by multiple mechanisms of action like inhibition of NF-kB, suppression of pro-inflammatory genes, etc. NRF2 is deacetylated by Sirtuins and therefore both have a direct association. Absence of SIRT indicates inhibition of NRF2 expression and thus no anti-oxidative and anti-inflammatory protection for the cell. Therefore, we propose that NRF2 activators and/or SIRT activators can be evaluated to check their efficacy in ameliorating the symptoms of COVID-19.

Keywords

COVID-19
NRF2
SIRT
ACE2
TMPRSS2
SIRT activators

Cited by (0)

View Abstract